Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | CPT1A | P50416 | 1/20 | 0.39 |
| ▸ | CPT1B | Q92523 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | GRM5 | P41594 | 3/20 | 0.38 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 3/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | PGR | P06401 | 1/20 | 0.37 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.37 |
| ▸ | CCR2 | P41597 | 1/20 | 0.36 |
| ▸ | ACLY | P53396 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29666248 | 1.00 | SMN1; SMN2 (0.45) | SMN1; SMN2NPSR1THRBHPGDCPT1A | |
| SCHEMBL23010499 | 0.89 | KMT2A (0.42) | SMN1; SMN2NPSR1THRBHPGDKMT2A | |
| SCHEMBL29666220 | 0.89 | KMT2A (0.42) | SMN1; SMN2NPSR1THRBHPGDKMT2A | |
| SCHEMBL29666217 | 0.88 | CA12 (0.43) | SMN1; SMN2KMT2AGAAMAPK1GRM5 | |
| SCHEMBL23010524 | 0.88 | CA12 (0.43) | SMN1; SMN2KMT2AGAAMAPK1GRM5 | |
| SCHEMBL22980412 | 0.87 | CA12 (0.41) | SMN1; SMN2THRBHPGDKMT2AGAA | |
| SCHEMBL29434896 | 0.87 | CA12 (0.41) | SMN1; SMN2THRBHPGDKMT2AGAA | |
| SCHEMBL22981714 | 0.87 | FFAR4 (0.39) | SMN1; SMN2THRBKMT2AGAAMAPK1 | |
| SCHEMBL29666164 | 0.87 | FFAR4 (0.39) | SMN1; SMN2THRBKMT2AGAAMAPK1 | |
| SCHEMBL22980410 | 0.86 | HSD11B1 (0.45) | SMN1; SMN2NPSR1CPT1ACPT1BGRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12065399-B2 | Arylsulfonamide derivatives | HOFFMANN-LA ROCHE INC. (US) | 2024-08-20 | — | — | US | claimed |
| EP-4013495-B1 | ARYLSULFONAMIDE DERIVATIVES AS MGLUR4 NEGATIVE ALLOSTERIC MODULATORS | HOFFMANN LA ROCHE (CH) | 2023-09-27 | — | — | EP | claimed |
| EP-4013495-A1 | ARYLSULFONAMIDE DERIVATIVES AS MGLUR4 NEGATIVE ALLOSTERIC MODULATORS | F. Hoffmann-La Roche AG (CH) | 2022-06-22 | — | — | EP | claimed |
| US-20220169599-A1 | ARYLSULFONAMIDE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2022-06-02 | — | — | US | claimed |
| CN-114174266-A | Arylsulfonamide derivatives as MGLUR4 negative allosteric modulators | 豪夫迈·罗氏有限公司 | 2022-03-11 | — | — | CN | claimed |
| WO-2021028512-A1 | ARYLSULFONAMIDE DERIVATIVES AS MGLUR4 NEGATIVE ALLOSTERIC MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2021-02-18 | — | — | WO | claimed |
| US-12065399-B2 | Arylsulfonamide derivatives | HOFFMANN-LA ROCHE INC. (US) | 2024-08-20 | — | — | US | disclosed |
| EP-4013495-B1 | ARYLSULFONAMIDE DERIVATIVES AS MGLUR4 NEGATIVE ALLOSTERIC MODULATORS | HOFFMANN LA ROCHE (CH) | 2023-09-27 | — | — | EP | disclosed |
| EP-4013495-B1 | ARYLSULFONAMIDE DERIVATIVES AS MGLUR4 NEGATIVE ALLOSTERIC MODULATORS | HOFFMANN LA ROCHE (CH) | 2023-09-27 | — | — | EP | disclosed |
| EP-4013495-A1 | ARYLSULFONAMIDE DERIVATIVES AS MGLUR4 NEGATIVE ALLOSTERIC MODULATORS | F. Hoffmann-La Roche AG (CH) | 2022-06-22 | — | — | EP | disclosed |
| US-20220169599-A1 | ARYLSULFONAMIDE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2022-06-02 | — | — | US | disclosed |
| US-20220169599-A1 | ARYLSULFONAMIDE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2022-06-02 | — | — | US | disclosed |
| CN-114174266-A | Arylsulfonamide derivatives as MGLUR4 negative allosteric modulators | 豪夫迈·罗氏有限公司 | 2022-03-11 | — | — | CN | disclosed |
| WO-2021028512-A1 | ARYLSULFONAMIDE DERIVATIVES AS MGLUR4 NEGATIVE ALLOSTERIC MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2021-02-18 | — | — | WO | disclosed |
| WO-2021028512-A1 | ARYLSULFONAMIDE DERIVATIVES AS MGLUR4 NEGATIVE ALLOSTERIC MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2021-02-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220169599-A1 | ARYLSULFONAMIDE DERIVATIVES | ARSA, SULT1E1, STS | SMN1; SMN2 1681/4885NPSR1 223/4885THRB 1952/4885 |
| US-12065399-B2 | Arylsulfonamide derivatives | ARSA, SULT1E1, STS | SMN1; SMN2 1681/4885NPSR1 223/4885THRB 1952/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.